Merck Articles
Eight novel disease-modifying therapies will drive modest growth in the multiple sclerosis drug market through 2019
13 July 2010
Brazil’s Eurofarma acquires Labs Gautier of Uruguay; EU clears Merck KGaA $7.2 billion buy of Millipore
9 July 2010
FDA Advisory Committee unanimously backs Gilenia, putting Novartis ahead in race for oral MS drug
11 June 2010
Merck Serono resubmits cladribine as a potential MS therapy in USA; GSK/HGS file Benlysta in Europe
8 June 2010
ASCO highlights include cancer drug news from Pfizer, Roche, Sanofi, Merck KGaA, Novartis and Eisai
7 June 2010
Clinical Data to pay $15.6 million milestone to Merck KGaA, as FDA accepts vilazodone filing
25 May 2010
Merck KGaA 1st-qtr 2010 net profit more than triples to 195 million euros, though pharma weak
28 April 2010
Neurologists eagerly await new oral treatment options for MS, such as EMD Serono's Movectro and Novartis' Gilenia
27 April 2010
Novartis’ MS drug Gilenia cuts relapse rates, moving it forward in race with Merck KGaA’s cladribine
13 April 2010
Merck KGaA pleased with Millipore buy, plans resubmission for cladribine and updates on Stimuvax
12 April 2010
Lpath gets $2 million milestone form Merck KGaA on completing Asonep Ph I study, but rejects opt-in extension
31 March 2010
Merck KGaA temporarily suspends cancer vaccine Stimuvax clinical program due to case of encephalitis
23 March 2010
Australian Judge rules against Merck & Co’s Vioxx, saying the pain drug is not fit for sale
5 March 2010
Drug's effect on reduction of new hip fractures is greatest influence on Rxing decisions, says DR report
5 March 2010
Big pharma struggles to benefit from increased CVD drug usage in market set to grow to $107 billion in 2018
3 March 2010
Merck & Co’s integrated pipeline has over 20 drugs and vaccines in late-stage development
2 March 2010
AstraZeneca opts to buy out rights to certain products from US Merck & Co JV for $647 million
2 March 2010
One cheer for Pfizer’s Fablyn
26 February 2010
Emerging oral atypical antipsychotics will garner only limited uptake in schizophrenia market
25 February 2010
AstraZeneca settles over transfer pricing in UK, agreeing to pay £505 million; GSK slumps on Avandia news
23 February 2010
Novartis’ Tasigna gets FDA priority review for early-stage CML and Gilenia for MS; also OK for meningitis vaccine Menveo
22 February 2010
US FDA calls for new safety controls on long-acting asthma drugs that could hit sales potential
19 February 2010
GlaxoSmithKline/XenoPort get negative response from USA’s FDA for Horizant; Merck & Co won’t file for vicriviroc now
18 February 2010
New Ph III data shows Merck & Co's Gardasil was effective against anal disease caused by HPV 6,11,16, and 18
18 February 2010
Merck & Co rises 2.3% as it beats 4th quarter 2009 sales forecast, boosted by Schering-Plough
17 February 2010
M&A - the trials and tribulations, as viewed by former Schering-Plough CEO Fred Hassan
17 February 2010
AHF takes campaign to Merck & Co’s home town with AIDS banners protesting high cost of Isentress
17 February 2010
Merck & Co returns rights to anti-fungal drug to Anacor
15 February 2010
Ulcerative colitis drug market will nearly double to $2.1 billion in 2018 in top seven markets
15 February 2010
BioSquare meeting identifies future trends, including patient-centered therapy and end to the blockbuster model
12 February 2010
Increasing competition from other biologics will continue to erode Enbrel's dominance in the psoriasis drug market, DR report concludes
12 February 2010
Merck & Co settles Vioxx law suits, agreeing to strengthen drug safety procedures and pay $12.2 million legal fees
11 February 2010
Merck & Co’s new combo asthma drug expected to garner peak year sales of over $250 million
10 February 2010
Licensing deals: Debiopharm/Novartis; Teva/Active Biotech; Qiagen on biomarker; Merck & Co/AnaptysBio; and Novavax/ROVI accord dropped
9 February 2010
Burst of M&A activity in pharma during 2009 led by mega-deals from Pfizer/Wyeth and Merck & Co/S-P
4 February 2010
Pharmaceutical M&A deals in 2009
4 February 2010
Spectrum Pharma licenses lymphoma drug belinostat from TopoTarget for up to $350 million
3 February 2010
Uptake of the first oral MS therapies will result in the market value peaking at $8.4 billion in 2013
1 February 2010
AstraZeneca to cut another 8,000 jobs as part of $1.8 billion cost-cutting program; unveils new R&D model
29 January 2010
European approval for Merck & Co’s Elonva and new indication for Roche’s Herceptin; Roche sets up Singapore research hub
28 January 2010
Setback for Merck & Co as vicriviroc disappoints in Ph III
22 January 2010
Promising results for Novartis and Merck KGaA oral MS drug trials represent "shifting tide"
22 January 2010
Japanese Pharma market seeing more foreign entrants
21 January 2010
Idera gets $4.3 million clinical milestone under its cancer drug deal with Merck KGaA
20 January 2010
Larger proportion of hepatitis C non-responder patients in USA will get telaprevir therapy than boceprevir, study shows
20 January 2010
Merck & Co aims to expand Gardasil usage to boost flagging sales
18 January 2010
“Extraordinary” drug price hikes identified by USA’s GAO
12 January 2010
Roche enters COPD sector with 400 million-plus-euro deal with Galapagos and antibody accord with AnaptysBio
12 January 2010
Mylan confirms first-to-file patent challenge to Cephalon’s sleep-disorder drug Nuvigil
12 January 2010
BioCryst names two additional Peramivir partnerships
12 January 2010
FDA finally approves Roche’s Actemra for moderately-to-severely active rheumatoid arthritis
11 January 2010
Blockbuster status predicted for co-formulation of rilpivirine and Truvada with sales of over $2 billion in the HIV Drug Market by 2018
7 January 2010
Merck & Co names former CDC boss Julie Gerberding president of its $5 billion vaccines business
22 December 2009
Merck & Co extends biotech reach with acquisition of UK’s Avecia
18 December 2009
UNITAID HIV patent pool could save over $1 billion a year, put pressure on AIDS drugmakers
17 December 2009
Merck & Co pays $52 million for Pfenex vaccine technology
14 December 2009
European Commission confirms further surprise inspections in the pharmaceutical sector
10 December 2009
Generic erosion will bite into the acute coronary syndrome market, cutting sales nearly 10% from 2008 to 2018
8 December 2009
Russia's hepatitis C virus drug market set to grow 9% annually, reaching $327 million by 2013
3 December 2009
UK Department of Health’s “money back” deal for MS drugs questioned; failing people with the disease
3 December 2009
US FDA delays Merck KGaA’s filing on MS drug cladribine
1 December 2009
Generics will continue to dominate Central and Eastern European pharma markets until 2011
30 November 2009
Merck KGaA's Erbitux boosts colorectal cancer survival rate
27 November 2009
Good and bad news for Idera Pharmaceuticals
26 November 2009
Big Pharma seeks to insulate itself from impact of ‘patent cliff’
24 November 2009
Merck KGaA gets second CHMP rejection for Erbitux in Advanced Non-Small Cell Lung Cancer
20 November 2009
CORRECTION: Merck and anacetrapib
19 November 2009
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
